We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
+4.3%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$192M
AUM Growth
+$59.6M
Cap. Flow
+$64.9M
Cap. Flow %
33.84%
Top 10 Hldgs %
51.67%
Holding
90
New
22
Increased
13
Reduced
5
Closed
18

Top Buys

Rank Stock Value
1
ALIM
Alimera Sciences
ALIM
+$9.7M
2
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$7.39M
3
SGMT icon
Sagimet Biosciences
SGMT
+$6.43M
4
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$6.39M
5
BHVN icon
Biohaven
BHVN
+$5.97M

Top Sells

Rank Stock Value
1
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$11.7M
2
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$4.23M
3
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$3.57M
4
GRI
GRI Bio
GRI
+$1.7M
5
HRMY icon
Harmony Biosciences
HRMY
+$1.14M

Sector Composition

Rank Sector Weight
1 Healthcare 88.02%
2 Consumer Staples 0.32%
3 Communication Services 0.27%
4 Materials 0.15%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ORIC icon
26
Oric Pharmaceuticals
ORIC
$1.34B
$2.53M 1.32%
+418,706
New +$3.43M
COGT icon
27
Cogent Biosciences
COGT
$7.14B
$2.29M 1.19%
235,000
– –
PHAT icon
28
Phathom Pharmaceuticals
PHAT
$679M
$2.28M 1.19%
220,000
+12,568
+6% +$172K
JSPR icon
29
Jasper Therapeutics
JSPR
$21.5M
$2.01M 1.05%
286,800
– –
ITCI
30
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$1.46M 0.76%
+28,000
New +$1.63M
SLNO
31
DELISTED
Soleno Therapeutics
SLNO
$1.39M 0.72%
+47,081
New +$285K
MRSN
32
DELISTED
Mersana Therapeutics
MRSN
$1.35M 0.7%
+42,365
New +$2.01M
DMAC icon
33
DiaMedica Therapeutics
DMAC
$365M
$1.28M 0.67%
+496,000
New +$1.59M
ACRS icon
34
PUT
Aclaris Therapeutics
ACRS
$851M
$1.2M 0.63%
+175,000
New +$1.5M
PRAX icon
35
Praxis Precision Medicines
PRAX
$10.3B
$1.11M 0.58%
43,333
-51,667
-54% -$977K
AVXL icon
36
CALL
Anavex Life Sciences
AVXL
$304M
$1.01M 0.53%
+154,900
New +$1.23M
AVXL icon
37
PUT
Anavex Life Sciences
AVXL
$304M
$1.01M 0.53%
+154,900
New +$1.23M
MRNS
38
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.01M 0.52%
+125,033
New +$1.04M
KPTI icon
39
Karyopharm Therapeutics
KPTI
$44.2M
$992K 0.52%
49,333
– –
FATBW
40
DELISTED
FAT Brands Inc. Warrant
FATBW
$974K 0.51%
200,000
-27,000
-12% -$110K
GRI
41
GRI Bio
GRI
$2.74M
$808K 0.42%
12
-15
-56% -$1.7M
SDOT icon
42
Sadot Group
SDOT
$13.3M
$605K 0.32%
+433
New +$937K
DDI
43
DoubleDown Interactive
DDI
$590M
$516K 0.27%
60,876
– –
SPRY icon
44
PUT
ARS Pharmaceuticals
SPRY
$551M
$378K 0.2%
+100,000
New +$656K
FNUC
45
Frontier Nuclear and Minerals Inc
FNUC
$43.2M
$290K 0.15%
+16,876
New +$419K
WLDSW icon
46
Wearable Devices Ltd Warrant
WLDSW
$132K
$168K 0.09%
1,961
– –
DRCTW
47
DELISTED
Direct Digital Holdings, Inc. Warrant
DRCTW
$108K 0.06%
180,000
– –
MBTCR
48
DELISTED
Nocturne Acquisition Corporation Right
MBTCR
$78.3K 0.04%
500,000
– –
NXGLW icon
49
NexGel Inc Warrant
NXGLW
$76.5K 0.04%
225,000
– –
CINGW icon
50
Cingulate Inc Warrants
CINGW
$35.4K
$44.5K 0.02%
270,000
– –
1
2
3 4

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return
SCM
Stadium Capital Management New Canaan, Connecticut $40.6M AUM 5.83% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return

Altium Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, Altium Capital Management held 90 positions worth $192M, up 45% from $132M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Altium Capital Management deployed $64.9M of net new capital in Q3 2023, opening 22 new positions and adding to 13 existing holdings. Its largest new stake was Alimera Sciences: 2,934,108 shares worth $9.1M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 92% a quarter earlier, followed by Consumer Staples and Communication Services.

On the sell side, the largest reduction was GRI Bio, an estimated $1.7M trimmed.

  • Altium Capital Management's largest Q3 2023 buy was Alimera Sciences: 2,934,108 shares worth $9.1M.
  • Altium Capital Management added most to Amylyx Pharmaceuticals in Q3 2023, an estimated $7.39M increase.
  • Altium Capital Management's biggest Q3 2023 reduction was GRI Bio, cutting an estimated $1.7M.
  • Altium Capital Management fully exited Chinook Therapeutics, Inc. Common Stock in Q3 2023, selling an estimated $11.7M.
  • Altium Capital Management's ten largest holdings make up 52% of its $192M portfolio in Q3 2023.
  • Altium Capital Management opened 22 new positions and closed 18 in Q3 2023.
  • Altium Capital Management's portfolio value rose 45% quarter-over-quarter to $192M.

Based on Altium Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.